ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Tuesday, November 9, 2021

8:30AM-10:30AM: Abstract Number: 1590

Sleep Disturbance Improves with SARS-COV2 Vaccinations in Patients with Rheumatologic and Chronic Inflammatory Diseases

Patient Outcomes, Preferences, & Attitudes Poster IV: COVID-19 (1589–1613)

8:30AM-10:30AM: Abstract Number: 1608

Sources of Information About SARS-CoV-2 Used by Patients with Chronic Inflammatory Rheumatic Diseases (CIRD)

Patient Outcomes, Preferences, & Attitudes Poster IV: COVID-19 (1589–1613)

8:30AM-10:30AM: Abstract Number: 1776

Stakeholder Outcome Prioritization in the Biologic Abatement and Capturing Kids’ Outcomes and Flare Frequency in Juvenile Spondyloarthritis Trial

Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster IV: Clinical Aspects of PsA & Peripheral SpA (1773–1800)

8:30AM-10:30AM: Abstract Number: 1644

Storytelling of Young Adults with Chronic Rheumatologic Illnesses: A Pilot Study

Pediatric Rheumatology – Clinical Poster III: Miscellaneous Rheumatic Disease (1614–1644)

8:30AM-10:30AM: Abstract Number: 1585

Suprascapular Nerve Block for the Treatment of Adhesive Capsulitis

Orthopedics, Low Back Pain, & Rehabilitation Poster (1584–1588)

8:30AM-10:30AM: Abstract Number: 1881

Surgical Outcomes After Operative Procedures in Patients with Behcet’s Disease

Vasculitis – Non-ANCA-Associated & Related Disorders Poster II (1862–1888)

8:30AM-10:30AM: Abstract Number: 1694

Sustainability of Response to Upadacitinib Among Patients with Active Rheumatoid Arthritis Refractory to Biological Disease-Modifying Anti-Rheumatic Drugs

RA – Treatments Poster III: RA Treatments & Their Safety (1674–1710)

8:30AM-10:30AM: Abstract Number: 1652

Symptom Burden in Anti-citrullinated Protein Antibody Positive Individuals At-risk for Rheumatoid Arthritis Is Changing over Time and Comparable to Patients with Early Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster IV: Outcomes, Trajectory of Disease, & Epidemiology (1645–1673)

8:30AM-10:30AM: Abstract Number: 1651

Symptom Trajectories in the Transition from Pre-Rheumatoid Arthritis to Clinically-Apparent Inflammatory Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster IV: Outcomes, Trajectory of Disease, & Epidemiology (1645–1673)

8:30AM-10:30AM: Abstract Number: 1552

Systemic Autoimmune Conditions and Hospital Admissions in Covid-19 Infection

Infection-related Rheumatic Disease Poster (1530–1564)

8:30AM-10:30AM: Abstract Number: 1877

Takayasu Arteritis Patients with Tuberculosis Have Unique Clinical Characteristics

Vasculitis – Non-ANCA-Associated & Related Disorders Poster II (1862–1888)

8:30AM-10:30AM: Abstract Number: 1728

Takayasu’s Arteritis and Pregnancy: A Meta-analysis

Reproductive Issues in Rheumatic Disorders Poster (1711–1731)

8:30AM-10:30AM: Abstract Number: 1804

Targeted Safety Analyses of Guselkumab (TREMFYA®): Long-term Results from Randomized Clinical Trials in Patients with Active Psoriatic Arthritis and Moderate to Severe Psoriasis

Spondyloarthritis Including PsA – Treatment Poster III: Psoriatic Arthritis II (1801–1835)

8:30AM-10:30AM: Abstract Number: 1606

Telemedicine for Rheumatology Care During the COVID-19 Pandemic: Patient Perceptions and Preferences

Patient Outcomes, Preferences, & Attitudes Poster IV: COVID-19 (1589–1613)

8:30AM-10:30AM: Abstract Number: 1716

Teratogenic Medication Use Associated with Favorable Odds of Contraception Counseling in a Cohort of Women with Systemic Lupus Erythematosus at a Large Tertiary Academic Medical Center

Reproductive Issues in Rheumatic Disorders Poster (1711–1731)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].